RxDoctor Payments Data

Gregory Backofen, MD

General Practice · El Dorado, ARNPI 1619231966

Payments from drug & device makers

$568in general payments, 2019–2025

Across 32 payments — averaging $17.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$179
  • Otsuka America Pharmaceutical, Inc.$142
  • Lilly USA, LLC$84
  • Tactile Systems Technology Inc$31
  • Pfizer$30
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$21
  • plus $81 from 5 others

What the payments were for

  • Food & beverage$568100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$568 in reported general payments places this provider in the 70th percentile of 720 general practice providers in Arkansas.

See all general practice providers in Arkansas

Medicare billing

Part B allowed, 2024
$21,009
Medicare patients
87
Services billed
278

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban439$173,970
OzempicSemaglutide98$102,100
TrulicityDulaglutide88$96,757
EnbrelEtanercept12$95,014
JardianceEmpagliflozin106$63,253
MounjaroTirzepatide44$56,884
NuplazidPimavanserin Tartrate20$49,352
FarxigaDapagliflozin Propanediol85$31,884
JanuviaSitagliptin Phosphate88$30,710
XareltoRivaroxaban85$30,283
Risperdal ConstaRisperidone Microspheres18$28,353
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog73$26,558
Trelegy ElliptaFluticasone/Umeclidin/Vilanter43$25,937
Breztri AerosphereBudesonide/Glycopyr/Formoterol39$25,810
LinzessLinaclotide31$20,438

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$30$173,970439 claims
Lilly USA, LLCTrulicity, Mounjaro$84$153,640132 claims
AstraZenecaFarxiga, Breztri Aerosphere$179$57,694124 claims
MerckJanuvia, Verquvo$13$39,369128 claims
Otsuka America Pharmaceutical, Inc.Rexulti$142$11,00012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 720 general practice providers in Arkansas.

Other general practice in El Dorado

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →